Scarica l'app Stockscreener
8.17
3.55%
0.28
Dopo l'orario di chiusura:
8.16
-0.010
-0.12%
Exagen Inc Borsa (XGN) Ultime notizie
Exagen Inc. (XGN) Stock Price & News - Syfe
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Eastern Progress
Exagen (XGN) Receives a Buy from Roth MKM - The Globe and Mail
EXAGEN INC. Q1 REVENUE USD 17.306 MILLION VS. IBES ESTIMATE USD 16.4 MILLION - Moomoo
Exagen Inc.(NasdaqGM: XGN) dropped from S&P Global BMI Index - marketscreener.com
Exagen Stock Price Forecast. Should You Buy XGN? - StockInvest.us
Exagen Inc.Common Stock (NQ: XGN - The Chronicle-Journal
Exagen Q2FY26 Results: Revenue hits record $19.9 million, EBITDA nears breakeven - scanx.trade
Full Transcript: Exagen Q2 2026 Earnings Call - Benzinga
XGN Looks 113.8% Overvalued on GF Value™ - GuruFocus
B. Riley Securities Initiates Exagen(XGN.US) With Buy Rating, Announces Target Price $12 - Moomoo
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control ProgressEarnings Manipulation Risk - dars.gov.et
Have Insiders Sold Exagen Shares Recently? - simplywall.st
XGN Q2 2026 Earnings: Loss Narrows on Strong EPS BeatOne-Time Loss Impact - dars.gov.et
Tax-driven stock sale and ESPP buy for Exagen (XGN) CFO - Stock Titan
XGN Q2 2026 Earnings: Loss Narrows to -$0.13, Delivering 32.26% EPS Surprise, Yet Shares Ease 1.73%Performance Review - dars.gov.et
XGN | Exagen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Exagen (XGN) director grant corrects prior option total - Stock Titan
Exagen (NASDAQ: XGN) grants director options at $4.31 strike - Stock Titan
Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31 - Stock Titan
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN - MarketBeat
GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN - MarketBeat
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentEarnings Acceleration Picks - vinanet.vn
XGN Q2 2026 Earnings: Narrower -$0.13 Loss Beats Estimates; Shares Slip 2.66%Retail Earnings Report - vinanet.vn
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exagen (XGN) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.25%EPS Growth Report - dars.gov.et
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN) - The Globe and Mail
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20% - Investing.com Nigeria
Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue H - GuruFocus
Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance - Yahoo Finance
Exagen Q2 2026 slides: record revenue, stock surges 30% on results - Investing.com
XGN: Record revenue, improved margins, and raised guidance highlight strong execution and growth - TradingView
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Exagen Q2 2026 slides: record revenue, stock surges 36% - Investing.com
Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results - MarketBeat
Exagen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance - ChartMill
EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XGN: Q2 2026 revenue rose 15.9% year-over-year, with improved margins and reduced net loss - TradingView
Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M - Stock Titan
Q2 2026 Exagen Inc Earnings Call Transcript - GuruFocus
Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance - Moomoo
Exagen Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Exagen reports Q2 2026 revenue $19.9M, narrows adjusted EBITDA loss to $0.1M - tradingview.com
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):